Citations (98)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Paul D. Miller. (2016) Management of severe osteoporosis. Expert Opinion on Pharmacotherapy 17:4, pages 473-488.
Read now
Read now
Stergios Balodimos, Kakia Nikolaou, Samuel Njau, Michael Karamouzis & Leda Kovatsi. (2015) The effect of opioid dependence on conventional and novel biochemical parameters of bone metabolism. The American Journal of Drug and Alcohol Abuse 41:6, pages 535-540.
Read now
Read now
Takanori Yamamoto, Mika Tsujimoto & Hideaki Sowa. (2015) Safety of daily teriparatide treatment: a post hoc analysis of a Phase III study to investigate the possible association of teriparatide treatment with calcium homeostasis in patients with serum procollagen type I N-terminal propeptide elevation. Clinical Interventions in Aging 10, pages 1101-1109.
Read now
Read now
Marie-Paule Lecart & Jean-Yves Reginster. (2011) Current options for the management of postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy 12:16, pages 2533-2552.
Read now
Read now
Claudia Gagnon, Vivien Li & Peter R Ebeling. (2008) Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment. Clinical Interventions in Aging 3:4, pages 635-645.
Read now
Read now
Samuel D. Vasikaran. (2008) Utility of Biochemical Markers of Bone Turnover and Bone Mineral Density in Management of Osteoporosis. Critical Reviews in Clinical Laboratory Sciences 45:2, pages 221-258.
Read now
Read now
Articles from other publishers (92)
E. Michael Lewiecki, Teresita Bellido, John P. Bilezikian, Jacques P. Brown, Azeez Farooki, Christopher S. Kovacs, Brendan Lee, William D. Leslie, Michael R. McClung, Mark L. Prasarn & Deborah E. Sellmeyer. (2023) Proceedings of the 2023 Santa Fe Bone Symposium: Progress and Controversies in the Management of Patients with Skeletal Diseases. Journal of Clinical Densitometry 26:4, pages 101432.
Crossref
Crossref
Marian Schini, Tatiane Vilaca, Fatma Gossiel, Syazrah Salam & Richard Eastell. (2023) Bone Turnover Markers: Basic Biology to Clinical Applications. Endocrine Reviews 44:3, pages 417-473.
Crossref
Crossref
Ayako Tominaga, Keiji Wada, Ken Okazaki, Hideharu Nishi, Yasushi Terayama, Shuji Shimamoto, Yasuteru Kodama & Yoshiharu Kato. (2023) Nonresponder Considerations for Romosozumab Treatment. Calcified Tissue International 113:2, pages 157-165.
Crossref
Crossref
Gosset Anna, Farcy Anne-Lise, Dufond Clémence, Pouillès Jean-Michel & Trémollieres Florence. (2023) Factors associated with bone response to teriparatide in young postmenopausal women with osteoporosis. Journal of Bone and Mineral Metabolism 41:2, pages 278-285.
Crossref
Crossref
Chung-An Chen, Ping-Yeh Chiu, Tse-Hao Huang, Natalie Yi-Ju Ho, Fu-Cheng Kao & Tsung-Ting Tsai. (2023) Quantitative lateral flow immunoassay for rapid detection of procollagen type I N-terminal propeptide in the monitoring of osteoporosis treatment. Analytica Chimica Acta 1239, pages 340695.
Crossref
Crossref
Jacques P. Brown, Andrew Don-Wauchope, Pierre Douville, Caroline Albert & Samuel D. Vasikaran. (2022) Current use of bone turnover markers in the management of osteoporosis. Clinical Biochemistry 109-110, pages 1-10.
Crossref
Crossref
Betty Ann Bjerkreim, Sara S Hammerstad & Erik Fink Eriksen. (2022) Bone Turnover in Relation to Thyroid-Stimulating Hormone in Hypothyroid Patients on Thyroid Hormone Substitution Therapy. Journal of Thyroid Research 2022, pages 1-6.
Crossref
Crossref
Christine M. Swanson, Prajakta Shanbhag, Emma J. Tussey, Corey A. Rynders, Kenneth P. WrightJrJr & Wendy M. Kohrt. (2022) Bone Turnover Markers After Six Nights of Insufficient Sleep and Subsequent Recovery Sleep in Healthy Men. Calcified Tissue International 110:6, pages 712-722.
Crossref
Crossref
A. Tominaga, K. Wada, K. Okazaki, H. Nishi, Y. Terayama, Y. Kodama & Y. Kato. (2022) Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment. Osteoporosis International 33:6, pages 1265-1273.
Crossref
Crossref
Asparuh Nikolov & Nikola Popovski. (2022) Extracellular Matrix in Heart Disease: Focus on Circulating Collagen Type I and III Derived Peptides as Biomarkers of Myocardial Fibrosis and Their Potential in the Prognosis of Heart Failure: A Concise Review. Metabolites 12:4, pages 297.
Crossref
Crossref
Fang-Ping Chen, Tsai-Sheng Fu, Yu-Ching Lin, Chen-Ming Sung, Mei-Huei Huang & Yu-Jr Lin. (2022) Association between P1NP and bone strength in postmenopausal women treated with teriparatide. Taiwanese Journal of Obstetrics and Gynecology 61:1, pages 91-95.
Crossref
Crossref
Fernando Marin & Yanfei L. Ma. 2022. Osteoporotic Fracture and Systemic Skeletal Disorders. Osteoporotic Fracture and Systemic Skeletal Disorders
339
359
.
Shoichi Ichimura. 2022. Osteoporotic Fracture and Systemic Skeletal Disorders. Osteoporotic Fracture and Systemic Skeletal Disorders
187
205
.
A. Tominaga, K. Wada, K. Okazaki, H. Nishi, Y. Terayama & Y. Kato. (2021) Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study. Osteoporosis International 32:10, pages 1999-2009.
Crossref
Crossref
A. Tominaga, K. Wada, Y. Kato, H. Nishi, Y. Terayama & K. Okazaki. (2020) Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study. Osteoporosis International 32:4, pages 653-661.
Crossref
Crossref
Pawel Szulc, Douglas C. Bauer & Richard Eastell. 2021. Marcus and Feldman's Osteoporosis. Marcus and Feldman's Osteoporosis
1545
1588
.
Andreas Fontalis & Richard Eastell. (2020) The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis. Bone 136, pages 115336.
Crossref
Crossref
Martin Birkhäuser. (2020) Monitoring der Frakturprävention mit Markern des KnochenstoffwechselsSurveillance de la prévention des fractures avec des marqueurs du métabolisme osseux. Journal für Gynäkologische Endokrinologie/Schweiz 23:2, pages 67-69.
Crossref
Crossref
Junichi Takada, Rajani Dinavahi, Akimitsu Miyauchi, Etsuro Hamaya, Toshiyasu Hirama, Cesar Libanati, Yoichi Nakamura, Cassandra E. Milmont & Andreas Grauer. (2019) Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial. Journal of Bone and Mineral Metabolism 38:3, pages 310-315.
Crossref
Crossref
Venkatesh Krishnan. 2020. Principles of Bone Biology. Principles of Bone Biology
971
981
.
Richard Eastell, Clifford J Rosen, Dennis M Black, Angela M Cheung, M Hassan Murad & Dolores Shoback. (2019) Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism 104:5, pages 1595-1622.
Crossref
Crossref
R. Eastell, B. H. Mitlak, Y. Wang, M. Hu, L. A. Fitzpatrick & D. M. Black. (2019) Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE. Osteoporosis International 30:3, pages 667-673.
Crossref
Crossref
So Young Park, Seong Hee AhnJun-Il YooYoun-Jee ChungYun Kyung Jeon, Byung-Ho Yoon, Ha Young Kim, Seung Hun LeeJehoon LeeSeongbin Hong. (2019) Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment. Journal of Bone Metabolism 26:4, pages 213.
Crossref
Crossref
Masayuki Miyagi, Hisako Fujimaki, Kouji Naruse, Kaori Suto, Gen Inoue, Toshiyuki Nakazawa, Takayuki Imura, Wataru Saito, Kentaro Uchida, Eiki Shirasawa, Naonobu Takahira & Masashi Takaso. (2019) The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients. Journal of Orthopaedic Science 24:1, pages 153-158.
Crossref
Crossref
Pawel Szulc. (2018) Bone turnover: Biology and assessment tools. Best Practice & Research Clinical Endocrinology & Metabolism 32:5, pages 725-738.
Crossref
Crossref
M.C. Vlot, M. den Heijer, R.T. de Jongh, M.G. Vervloet, W.F. Lems, R. de Jonge, B. Obermayer-Pietsch & A.C. Heijboer. (2018) Clinical utility of bone markers in various diseases. Bone 114, pages 215-225.
Crossref
Crossref
M. A. Paggiosi, L. Yang, D. Blackwell, J. S. Walsh, E. McCloskey, N. Peel & R. Eastell. (2018) Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study. Osteoporosis International 29:6, pages 1367-1378.
Crossref
Crossref
Richard Eastell, Tom Pigott, Fatma Gossiel, Kim E Naylor, Jennifer S Walsh & Nicola F A Peel. (2018) DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful?. European Journal of Endocrinology 178:1, pages R19-R31.
Crossref
Crossref
Christine M Swanson, Steven A Shea, Pamela Wolfe, Sean W Cain, Mirjam Munch, Nina Vujović, Charles A Czeisler, Orfeu M Buxton & Eric S Orwoll. (2017) Bone Turnover Markers After Sleep Restriction and Circadian Disruption: A Mechanism for Sleep-Related Bone Loss in Humans. The Journal of Clinical Endocrinology & Metabolism 102:10, pages 3722-3730.
Crossref
Crossref
MUTSUMI HARADA, KEISHOKU SAKURABA, SHIMPEI FUJITA, HIROYUKI TOMITA, ATSUSHI KUBOTA, MINORU KANO & KENTA WAKAMATSU. (2017) The Study of Bone Metabolism Markers in Male College Artistic Gymnasts. Juntendo Medical Journal 63:3, pages 186-194.
Crossref
Crossref
R. Niimi, T. Kono, A. Nishihara, M. Hasegawa, T. Kono & A. Sudo. (2016) A retrospective analysis of nonresponse to daily teriparatide treatment. Osteoporosis International 27:9, pages 2845-2853.
Crossref
Crossref
Astrid Fahrleitner-Pammer, David Burr, Harald Dobnig, Jan J. Stepan, Helmut Petto, Jiliang Li, John H. Krege & Imre Pavo. (2016) Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment. Bone 89, pages 16-24.
Crossref
Crossref
E. Cavalier, P. Bergmann, O. Bruyère, P. Delanaye, A. Durnez, J.-P. Devogelaer, S. L. Ferrari, E. Gielen, S. Goemaere, J.-M. Kaufman, A. Nzeusseu Toukap, J.-Y. Reginster, A.-F. Rousseau, S. Rozenberg, A. J. Scheen & J.-J. Body. (2016) The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. Osteoporosis International 27:7, pages 2181-2195.
Crossref
Crossref
Erik Fink Eriksen & Jacques P. Brown. (2016) Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics. Bone 86, pages 139-142.
Crossref
Crossref
Samuel D. Vasikaran & S. A. Paul Chubb. (2016) The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis. Endocrine 52:2, pages 222-225.
Crossref
Crossref
Shinichi Nakatoh. (2015) The importance of assessing the rate of bone turnover and the balance between bone formation and bone resorption during daily teriparatide administration for osteoporosis: a pilot study. Journal of Bone and Mineral Metabolism 34:2, pages 216-224.
Crossref
Crossref
Cyrus Cooper, Thomas Bardin, Maria-Luisa Brandi, Patrice Cacoub, John Caminis, Roberto Civitelli, Maurizio Cutolo, Willard Dere, Jean-Pierre Devogelaer, Adolfo Diez-Perez, Thomas A. Einhorn, Patrick Emonts, Olivier Ethgen, John A. Kanis, Jean-Marc Kaufman, Tore K. Kvien, Willem F. Lems, Eugene McCloskey, Pierre Miossec, Susanne Reiter, Johann Ringe, René Rizzoli, Kenneth Saag & Jean-Yves Reginster. (2016) Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Aging Clinical and Experimental Research 28:1, pages 1-16.
Crossref
Crossref
K. E. Naylor, R. M. Jacques, M. Paggiosi, F. Gossiel, N. F. A. Peel, E. V. McCloskey, J. S. Walsh & R. Eastell. (2015) Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporosis International 27:1, pages 21-31.
Crossref
Crossref
L A Marchenkova & E Yu Martynova. (2015) THE RELEVANCE, BENEFITS AND CLINICAL PERSPECTIVES OF THE COMBINED TREATMENT OF OSTEOPOROSIS BASED ON BONE-ANABOLIC THERAPY. Osteoporosis and Bone Diseases 18:2, pages 20-24.
Crossref
Crossref
Núria Guañabens, Pilar Peris & Ana Monegal. (2015) Bone Turnover Markers: A Clinical Review. Clinical Reviews in Bone and Mineral Metabolism 13:2, pages 83-97.
Crossref
Crossref
S.A. Paul Chubb, Christine D. Mandelt & Samuel D. Vasikaran. (2015) Comparison of results from commercial assays for plasma CTX: The need for harmonization. Clinical Biochemistry 48:7-8, pages 519-524.
Crossref
Crossref
Jean-Philippe Bonjour, Wendy Kohrt, Régis Levasseur, Michelle Warren, Susan Whiting & Marius Kraenzlin. (2014) Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products. Nutrition Research Reviews 27:2, pages 252-267.
Crossref
Crossref
J. H. Krege, N. E. Lane, J. M. Harris & P. D. Miller. (2014) PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporosis International 25:9, pages 2159-2171.
Crossref
Crossref
Samuel D. Vasikaran, S.A. Paul Chubb & Hans-Gerhard Schneider. (2014) Towards optimising the provision of laboratory services for bone turnover markers. Pathology 46:4, pages 267-273.
Crossref
Crossref
M. Baldini, S. Forti, A. Orsatti, A. Marcon, F.M. Ulivieri, L. Airaghi, L. Zanaboni & M.D. Cappellini. (2014) Thalassemic osteopathy: A new marker of bone deposition. Blood Cells, Molecules, and Diseases 52:2-3, pages 91-94.
Crossref
Crossref
R. Niimi, T. Kono, A. Nishihara, M. Hasegawa, A. Matsumine, T. Nakamura, T. Kono & A. Sudo. (2013) An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide. Osteoporosis International 25:1, pages 377-384.
Crossref
Crossref
P. Farahmand, F. Marin, F. Hawkins, R. Möricke, J. D. Ringe, C.-C. Glüer, N. Papaioannou, S. Minisola, G. Martínez, J. M. Nolla, C. Niedhart, N. Guañabens, R. Nuti, E. Martín-Mola, F. Thomasius, J. Peña, C. Graeff, G. Kapetanos, H. Petto, A. Gentzel, A. Reisinger & P. K. Zysset. (2013) Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporosis International 24:12, pages 2971-2981.
Crossref
Crossref
Sonsoles Botella, Patricia Restituto, Ignacio Monreal, Inmaculada Colina, Amparo Calleja & Nerea Varo. (2013) Traditional and Novel Bone Remodeling Markers in Premenopausal and Postmenopausal Women. The Journal of Clinical Endocrinology & Metabolism 98:11, pages E1740-E1748.
Crossref
Crossref
Pawel Szulc & Douglas C. Bauer. 2013. Osteoporosis. Osteoporosis
1573
1610
.
William D. Fraser, Kay W. Colston & John C. Stevenson. 2013. The Immunoassay Handbook. The Immunoassay Handbook
705
720
.
J. A. Kanis, E. V. McCloskey, H. Johansson, C. Cooper, R. Rizzoli & J.-Y. Reginster. (2012) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International 24:1, pages 23-57.
Crossref
Crossref
Emmanuel Biver. (2012) Use of bone turnover markers in clinical practice. Current Opinion in Endocrinology, Diabetes & Obesity 19:6, pages 468-473.
Crossref
Crossref
S. Lekamwasam, J. D. Adachi, D. Agnusdei, J. Bilezikian, S. Boonen, F. Borgström, C. Cooper, A. Diez Perez, R. Eastell, L. C. Hofbauer, J. A. Kanis, B. L. Langdahl, O. Lesnyak, R. Lorenc, E. McCloskey, O. D. Messina, N. Napoli, B. Obermayer-Pietsch, S. H. Ralston, P. N. Sambrook, S. Silverman, M. Sosa, J. Stepan, G. Suppan, D. A. Wahl & J. E. Compston. (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporosis International 23:9, pages 2257-2276.
Crossref
Crossref
Richard Eastell, Richard Jacques & Kim Naylor. (2012) Monitoring anti-resorptive treatments for osteoporosis using bone turnover markers. IBMS BoneKEy 9.
Crossref
Crossref
Marja-Kaisa Koivula, Leila Risteli & Juha Risteli. (2012) Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. Clinical Biochemistry 45:12, pages 920-927.
Crossref
Crossref
Pawel Szulc. (2012) The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis. Clinical Biochemistry 45:12, pages 907-919.
Crossref
Crossref
Nelson B. Watts, Robert A. Adler, John P. Bilezikian, Matthew T. Drake, Richard Eastell, Eric S. Orwoll & Joel S. Finkelstein. (2012) Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism 97:6, pages 1802-1822.
Crossref
Crossref
Carmen M. Romero Barco, Sara Manrique Arija & Manuel Rodríguez Pérez. (2012) Biochemical Markers in Osteoporosis: Usefulness in Clinical Practice. Reumatología Clínica (English Edition) 8:3, pages 149-152.
Crossref
Crossref
John T. Schousboe & Douglas C. Bauer. (2012) Clinical Use of Bone Turnover Markers to Monitor Pharmacologic Fracture Prevention Therapy. Current Osteoporosis Reports 10:1, pages 56-63.
Crossref
Crossref
Jehoon LeeSamuel Vasikaran. (2012) Current Recommendations for Laboratory Testing and Use of Bone Turnover Markers in Management of Osteoporosis. Annals of Laboratory Medicine 32:2, pages 105.
Crossref
Crossref
Lluis Pérez Edo, Alberto Alonso Ruiz, Daniel Roig Vilaseca, Alberto García Vadillo, Nuria Guañabens Gay, Pilar Peris, Antonio Torrijos Eslava, Chesús Beltrán Audera, Jordi Fiter Aresté, Luis Arboleya Rodríguez, Jenaro Graña Gil, Jordi Carbonell Abelló, Joan Miquel Nolla, Susana Holgado Pérez, Esteban Salas Heredia, Jaime Zubieta Tabernero, Javier Del Pino Montes, Josep Blanch i. Rubió, Manuel Caamaño Freire, Manuel Rodríguez Pérez, Santos Castañeda, Dacia Cerdá, Carmen Gómez Vaquero, Javier Calvo Catalá, Manel Ciria & Estíbaliz Loza. (2011) 2011 Up-Date of the Consensus Statement of the Spanish Society of Rheumatology on Osteoporosis. Reumatología Clínica (English Edition) 7:6, pages 357-379.
Crossref
Crossref
Lluís Pérez Edo, Alberto Alonso Ruiz, Daniel Roig Vilaseca, Alberto García Vadillo, Nuria Guañabens Gay, Pilar Peris, Antonio Torrijos Eslava, Chesús Beltrán Audera, Jordi Fiter Aresté, Luis Arboleya Rodríguez, Jenaro Graña Gil, Jordi Carbonell Abelló, Joan Miquel Nolla, Susana Holgado Pérez, Esteban Salas Heredia, Jaime Zubieta Tabernero, Javier Del Pino Montes, Josep Blanch i Rubió, Manuel Caamaño Freire, Manuel Rodríguez Pérez, Santos Castañeda, Dacia Cerdá, Carmen Gómez Vaquero, Javier Calvo Catalá, Manel Ciria & Estíbaliz Loza. (2011) Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis. Reumatología Clínica 7:6, pages 357-379.
Crossref
Crossref
Thomas Funck-Brentano, Emmanuel Biver, Florence Chopin, Beatrice Bouvard, Guillaume Coiffier, Jean-Claude Souberbielle, Patrick Garnero & Christian Roux. (2011) Clinical Utility of Serum Bone Turnover Markers in Postmenopausal Osteoporosis Therapy Monitoring: A Systematic Review. Seminars in Arthritis and Rheumatism 41:2, pages 157-169.
Crossref
Crossref
Carmen M. Romero Barco, Sara Manrique Arija & Manuel Rodríguez Pérez. (2011) Marcadores bioquímicos en osteoporosis. Utilidad en la práctica clínica. Reumatología Clínica.
Crossref
Crossref
R. Eastell, A. Rogers, X. Ni & J. H. Krege. (2010) Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide. Osteoporosis International 22:6, pages 1927-1934.
Crossref
Crossref
A. Blumsohn, F. Marin, T. Nickelsen, K. Brixen, G. Sigurdsson, J. González de la Vera, S. Boonen, S. Liu-Léage, C. Barker & R. Eastell. (2010) Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporosis International 22:6, pages 1935-1946.
Crossref
Crossref
Mika Tsujimoto, Peiqi Chen, Akimitsu Miyauchi, Hideaki Sowa & John H. Krege. (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 48:4, pages 798-803.
Crossref
Crossref
S. Vasikaran, R. Eastell, O. Bruyère, A. J. Foldes, P. Garnero, A. Griesmacher, M. McClung, H. A. Morris, S. Silverman, T. Trenti, D. A. Wahl, C. Cooper & J. A. Kanis. (2010) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis International 22:2, pages 391-420.
Crossref
Crossref
J. J. Stepan, D. B. Burr, J. Li, Y. L. Ma, H. Petto, A. Sipos, H. Dobnig, A. Fahrleitner-Pammer, D. Michalská & I. Pavo. (2010) Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporosis International 21:12, pages 2027-2036.
Crossref
Crossref
Akimitsu Miyauchi, Toshio Matsumoto, Toshitsugu Sugimoto, Mika Tsujimoto, Margaret R. Warner & Toshitaka Nakamura. (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:3, pages 493-502.
Crossref
Crossref
Alan L. Burshell, Rüdiger Möricke, Ricardo Correa-Rotter, Peiqi Chen, Margaret R. Warner, Gail P. Dalsky, Kathleen A. Taylor & John H. Krege. (2010) Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 46:4, pages 935-939.
Crossref
Crossref
Richard Eastell, Peiqi Chen, Kenneth G. Saag, Alan L. Burshell, Mayme Wong, Margaret R. Warner & John H. Krege. (2010) Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 46:4, pages 929-934.
Crossref
Crossref
Patrícia Dreyer & José Gilberto H. Vieira. (2010) Bone turnover assessment: a good surrogate marker?. Arquivos Brasileiros de Endocrinologia & Metabologia 54:2, pages 99-105.
Crossref
Crossref
Kathryn M. Ryder, S. Bobo Tanner, Laura Carbone, John E. Williams, Henry M. Taylor, Andrew Bush, Victorina Pintea & Mitchell A. Watsky. (2009) Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis. Journal of Bone and Mineral Metabolism 28:2, pages 233-239.
Crossref
Crossref
Christian Meier, Markus J. Seibel & Marius E. Kraenzlin. 2010. Osteoporosis. Osteoporosis
131
155
.
A P Courtney, P Holloway & A Fairney. (2009) Stability of serum total N-terminal propeptide of type I collagen. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 46:6, pages 533-534.
Crossref
Crossref
Jacques P. Brown, Caroline Albert, Bassam A. Nassar, Jonathan D. Adachi, David Cole, K. Shawn Davison, Kent C. Dooley, Andrew Don-Wauchope, Pierre Douville, David A. Hanley, Sophie A. Jamal, Robert Josse, Stephanie Kaiser, John Krahn, Richard Krause, Richard Kremer, Raymond Lepage, Elaine Letendre, Suzanne Morin, Daylily S. Ooi, Alexandra Papaioaonnou & Louis-Georges Ste-Marie. (2009) Bone turnover markers in the management of postmenopausal osteoporosis. Clinical Biochemistry 42:10-11, pages 929-942.
Crossref
Crossref
Athanasios D. Anastasilakis, Dimirtios G. Goulis, Stergios A. Polyzos, Spiridon Gerou, Iris Ballaouri, Zoe Efstathiadou, Marina Kita & Avraam Avramidis. (2009) No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial. Clinical Endocrinology 70:4, pages 522-526.
Crossref
Crossref
Akimitsu Miyauchi, Toshio Matsumoto, Hirofumi Shigeta, Mika Tsujimoto, Daniel Thiebaud & Toshitaka Nakamura. (2008) Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study. Journal of Bone and Mineral Metabolism 26:6, pages 624-634.
Crossref
Crossref
Michael SamoszukMichael LeutherNicholas Hoyle. (2008) Role of serum P1NP measurement for monitoring treatment response in osteoporosis. Biomarkers in Medicine 2:5, pages 495-508.
Crossref
Crossref
Barbara M Obermayer-Pietsch, Fernando Marin, Eugene V McCloskey, Peyman Hadji, Jordi Farrerons, Steven Boonen, Maurice Audran, Clare Barker, Athanasios D Anastasilakis, William D Fraser & Thomas Nickelsen. (2008) Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment. Journal of Bone and Mineral Research 23:10, pages 1591-1600.
Crossref
Crossref
Adriana Pérez, María Ulla, Beatriz García, María Lavezzo, Eliana Elías, Miriam Binci, María Rivoira, Viviana Centeno, Arturo Alisio & Nori Tolosa de Talamoni. (2008) Genotypes and clinical aspects associated with bone mineral density in Argentine postmenopausal women. Journal of Bone and Mineral Metabolism 26:4, pages 358-365.
Crossref
Crossref
A. D. Anastasilakis, D. G. Goulis, S. A. Polyzos, S. Gerou, G. N. Koukoulis, Z. Efstathiadou, M. Kita & A. Avramidis. (2008) Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. International Journal of Clinical Practice 62:6, pages 919-924.
Crossref
Crossref
Jean-Yves Reginster, Julien Collette, Audrey Neuprez, Brigitte Zegels, Rita Deroisy & Olivier Bruyere. (2008) Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 42:5, pages 832-836.
Crossref
Crossref
Jeffrey Stroup, Michael P. Kane & Asim M. Abu-Baker. (2008) Teriparatide in the treatment of osteoporosis. American Journal of Health-System Pharmacy 65:6, pages 532-539.
Crossref
Crossref
David A. Hanley, Patricia H. Watson, Anthony B. Hodsman & David W. Dempster. 2008. Principles of Bone Biology. Principles of Bone Biology
1659
1695
.
. 2008. Orthopedic Traumatology - A Resident's Guide. Orthopedic Traumatology - A Resident's Guide
177
201
.
Bess Dawson-Hughes, Peiqi Chen & John H. Krege. (2007) Response to Teriparatide in Patients with Baseline 25-Hydroxyvitamin D Insufficiency or Sufficiency. The Journal of Clinical Endocrinology & Metabolism 92:12, pages 4630-4636.
Crossref
Crossref
Paul D. Miller, John P. Bilezikian, Manuel Diaz-Curiel, Peiqi Chen, Fernando Marin, John H. Krege, Mayme Wong & Robert Marcus. (2007) Occurrence of Hypercalciuria in Patients with Osteoporosis Treated with Teriparatide. The Journal of Clinical Endocrinology & Metabolism 92:9, pages 3535-3541.
Crossref
Crossref
Marius E Kraenzlin. (2007) Biochemical markers of bone turnover and osteoporosis management. BoneKEy-Osteovision 4:7, pages 191-203.
Crossref
Crossref
G. Gascoin-Lachambre, C. Trivin, R. Brauner & J.-C. Souberbielle. (2007) Serum procollagen type 1 amino-terminal propeptide (P1NP) as an early predictor of the growth response to growth hormone treatment: Comparison of intrauterine growth retardation and idiopathic short stature. Growth Hormone & IGF Research 17:3, pages 194-200.
Crossref
Crossref
P. D. Miller, E. N. Schwartz, P. Chen, D. A. Misurski & J. H. Krege. (2006) Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International 18:1, pages 59-68.
Crossref
Crossref